Abstract | BACKGROUND: In- stent restenosis remains a pivotal problem after coronary and peripheral stenting. Sonodynamic therapy inhibits tumor growth by means of cytotoxicity after the activation of sonochemical sensitizers by ultrasound. PAD-S31 is known to be a water-soluble, chlorin-derivative sonochemical sensitizer. We assessed the efficacy of sonodynamic therapy using this sensitizer on neointimal hyperplasia in a rabbit stent model. METHODS AND RESULTS:
Stents were implanted in the iliac arteries of 16 rabbits. A total of 32 stented arteries were randomized to sonodynamic therapy, control, ultrasound exposure, and PAD-S31 groups. One hour after the intravenous administration of PAD-S31 (25 mg/kg body weight), ultrasound energy (1 MHz, 0.3 W/cm(2)) was delivered transdermally to the sonodynamic therapy group. At 28 days, all stent sites were analyzed morphometrically. The size of the intimal cross-sectional area was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD-S31 groups (0.31+/-0.07 versus 1.38+/-0.47, 1.66+/-0.71, and 1.61+/-0.42 mm(2), respectively; P<0.05). The ratio of the intimal and medial cross-sectional area was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD-S31 groups (0.71+/-0.22 versus 2.53+/-1.39, 2.48+/-0.60, and 3.45+/-1.42 mm(2); P<0.05). CONCLUSIONS: Sonodynamic therapy with PAD-S31 is considered to be a feasible treatment modality for noninvasively inhibiting neointimal hyperplasia in a rabbit iliac stent model.
|
Authors | Koh Arakawa, Kousukue Hagisawa, Hiroyuki Kusano, Satoru Yoneyama, Akira Kurita, Tsunenori Arai, Makoto Kikuchi, Isao Sakata, Shin-ichirou Umenura Si, Fumitaka Ohsuzu |
Journal | Circulation
(Circulation)
Vol. 105
Issue 2
Pg. 149-51
(Jan 15 2002)
ISSN: 1524-4539 [Electronic] United States |
PMID | 11790692
(Publication Type: Evaluation Study, Journal Article)
|
Chemical References |
- 13,17-bis(1-carboxypropionyl)carbamoylethyl-3-ethenyl-8-ethoxyiminoethylidene-7-hydroxy-2,7,12,18-tetramethyl porphyrin
- Porphyrins
|
Topics |
- Animals
- Combined Modality Therapy
- Graft Occlusion, Vascular
(etiology, pathology, therapy)
- Hyperplasia
(etiology, pathology, therapy)
- Iliac Artery
(pathology)
- Porphyrins
(therapeutic use)
- Rabbits
- Stents
(adverse effects)
- Ultrasonic Therapy
(methods)
|